Health Affairs · 2001 · 88 citations · 2 references
PharmacyPharmaceutical PolicyPharmacoeconomicsCost-effectiveness AnalysisDrug Approval ProcessesPharmacoeconomic ModelingDrug EvaluationPharmaceutical EconomicsPharmaceutical MarketingPharmacoeconomic EvaluationPrescription Drug CoveragePrescription Drug PolicyCost-effectivenessDrug Cost AnalysisDrug Subsidy PolicyMedicines Pricing PolicyPharmaceutical Cost AnalysisPharmaceutical Subsidy PolicyPrescription Drug SubsidiesSubsidy Financing
The Australian government offers its citizens subsidies on a select list of pharmaceuticals. For a drug to qualify for inclusion on this list, its manufacturer must demonstrate that the drug is both clinically effective and cost-effective. In part, this measure, along with others, was introduced to improve clinical and economic outcomes. Although this evidence-based system has provided transparency and consistency in decision making about which drugs will be covered, it may not have contained the rate of increase in drug costs.
2
Problems With the Interpretation of Pharmacoeconomic Analyses
Suzanne Hill, Andrew Mitchell, David Henry · JAMA · 2000 · 228 citations